ARTICLE | Top Story
Exelixis, Merck in PI3K delta deal
December 22, 2011 1:21 AM UTC
Exelixis Inc (NASDAQ:EXEL) granted Merck & Co. Inc. (NYSE:MRK) exclusive, worldwide rights its preclinical phosphoinositide 3-kinase (PI3K) delta program, including lead inhibitor XL499 and related co...